DTX3 promotes anti-tumor immunity by inducing PD-L1 ubiquitination and is suppressed by p65/miR-222 in bladder cancer.
Targeting a specific protein improves anti-PD-1 immunotherapy response in bladder cancer, suggesting a path to overcome treatment resistance.
The limited efficacy of programmed death ligand-1 (PD-L1)/programmed death 1 (PD-1) immunotherapy remains a major challenge in bladder cancer (BC). DTX3 overexpression combined with anti-PD-1 mAb produced significantly stronger anti-tumor effects than either monotherapy in syngeneic mouse models.
What the study was
- Study design
- Animal model study
- Population
- cancer patients
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Oncogene
Why it surfaced
Score 5/10 [PROMISING_PRELIMINARY]: Animal model study (Journal Article) matched 'Novel therapeutics: immunotherapy, CAR-T'. Components — novelty:1/3, relevance:2/3, design:1/2, population:1/2. Confidence: high. Conservative scoring applied per v1.3 rubric.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.